SGEN Seattle Genetics, Inc.

120.702.82 (+2.39%)
IEX price: 3:59:27 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$51.50-$118.31
Volume
1,614,985
Avg Volume
1,143,715
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$20.69B
Enterprise Value (EV)
$19.79B
PE Ratio
-
EV/EBITDA
-84.59
Price/Sales
30.86
Price/Book
16.26
PEG Ratio
2.09

Financials

Revenue
$654.70M
Gross Profit
$566.41M
EBITDA
-$233.97M
EPS, ttm
-$1.87
Profit Margin
-
Revenue/Employee
$502.84K
Next Earnings Date
2/13/2020 (85 days)
Debt to Equity
-
Debt
-
Cash
$410.67M
Net Debt
-

Performance

Beta
1.27
200 Day Moving Avg
$76.45
50 Day Moving Avg
$91.23
52 Week Change
109.79%
YTD Change
107.44%
1 Month Change
16.84%
3 Month Change
49.92%
6 Month Change
83.10%
1 Year Change
109.79%
2 Year Change
100.82%
5 Year Change
225.28%

Share Count

Shares Outstanding
171.4M
Float
169.4M
Restricted Shares
1.9M
Restricted Shares, %
1.14%

Seattle Genetics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Clay B. Siegall

Website: http://www.seattlegenetics.com

Description: Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Employees: 1,302

Latest News